Tag Archives: Ewing Sarcoma

April, 2017

10 April
FDA Grants Orphan Drug Status to NantCell’s Ganitumab in Ewing Sarcoma

CULVER CITY, Calif.–(BUSINESS WIRE)–NantCell, Inc., part of the NantWorks ecosystem of companies, announced today that the FDA has granted Orphan Drug Designation to the company’s Ganitumab, Insulin Growth Factor-1R (IGF-1R) monoclonal antibody therapy for the treatment of patients with Ewing sarcoma. Ganitumab is a fully human monoclonal antibody directed against IGF-1R that is being investigated …
Share

20 June
Oncternal’s Ewing Sarcoma Drug Receives Fast Track Designation from the FDA

SAN DIEGO, June 20, 2016 /PRNewswire/ — Oncternal Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapies for rare and common malignancies, today announced that its ets-family inhibitor TK216 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with Ewing sarcoma …
Share